Roche?s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase tria
- Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress
- 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alteration status